{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:18:10Z","timestamp":1788254290117,"version":"build-2803163510"},"reference-count":138,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Over the last decade, numerous studies have investigated the administration of monoclonal anti-amyloid antibodies (AAAs) as a therapeutic approach in Alzheimer\u2019s disease (AD). The purpose of this umbrella review is to summarize current knowledge concerning the efficacy and safety of FDA- and EMA-approved AAAs for AD, namely, lecanemab and donanemab. Methods: We conducted a literature search in the PubMed, Scopus, and Web of Science databases in English, focusing on systematic reviews and\/or meta-analyses, assessed by AMSTAR 2, concerning clinical and imaging efficacy, i.e., cognitive improvement and reduction of beta-amyloid on PET scan, as well as safety, i.e., adverse events and amyloid-related imaging abnormalities (ARIA). The extracted review-level dataset was entered into SPSS Version 26 for descriptive statistical analysis. Results: This umbrella review included 11 systematic reviews and\/or meta-analyses. Patients treated with lecanemab or donanemab showed statistically significant changes on cognitive scales such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB) (mean effect estimate \u22120.485, SD = 0.152, \u22120.70 to \u22120.34) and the Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), but most were below or around clinically meaningful thresholds. Lecanemab and donanemab showed a statistically significant decrease in amyloid PET outcomes, including centiloids or the standardized uptake value ratio. Both antibodies were linked to ARIA, including amyloid-related imaging abnormalities-edema (ARIA-E OR 8.32\u201312.26) and amyloid-related imaging abnormalities-hemorrhage (ARIA-H OR 2\u20135.77), especially in ApoE\u03b54 carriers. Conclusions: Lecanemab and donanemab are biologically active drugs for the treatment of early AD, with cognitive benefits below or around the clinically meaningful threshold. They are, however, associated with increased ARIA risk. Their administration depends upon careful patient selection, shared decision-making, and clear communication regarding expectations.<\/jats:p>","DOI":"10.3390\/jcm15176782","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"6782","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-Amyloid Antibodies in the Treatment of Alzheimer\u2019s Disease: An Umbrella Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4541-5384","authenticated-orcid":false,"given":"Stefania","family":"Kalampokini","sequence":"first","affiliation":[{"name":"1st Department of Neurology, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8156-4440","authenticated-orcid":false,"given":"Iraklis","family":"Keramidiotis","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2666-8183","authenticated-orcid":false,"given":"Antonis","family":"Frontistis","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zuchi","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Michmizos","sequence":"additional","affiliation":[{"name":"Medical School of Aristotle, University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-0290","authenticated-orcid":false,"given":"Vasileios","family":"Papaliagkas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-3749","authenticated-orcid":false,"given":"Effrosyni","family":"Koutsouraki","sequence":"additional","affiliation":[{"name":"1st Department of Neurology, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Twiss, E., McPherson, C., and Weaver, D.F. (2025). Global Diseases Deserve Global Solutions: Alzheimer\u2019s Disease. Neurol. Int., 17.","DOI":"10.3390\/neurolint17060092"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Liu, W., Deng, W., Gong, X., Ou, J., Yu, S., and Chen, S. (2025). Global burden of Alzheimer\u2019s disease and other dementias in adults aged 65 years and over, and health inequality related to SDI, 1990\u20132021: Analysis of data from GBD 2021. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-22378-z"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Schindler","year":"2024","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10412","DOI":"10.1038\/s41467-025-66728-2","article-title":"Blood biomarkers of Alzheimer\u2019s disease and progression across different stages of cognitive decline in the community","volume":"16","author":"Valletta","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/nep3.58","article-title":"Blood-based biomarkers of Alzheimer\u2019s disease: Standardization and comprehensiveness","volume":"2","author":"Liu","year":"2024","journal-title":"Neuroprotection"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","article-title":"Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease","volume":"30","author":"Jack","year":"2024","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment Combinations for Alzheimer\u2019s Disease: Current and Future Pharmacotherapy Options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115522","DOI":"10.1016\/j.bcp.2023.115522","article-title":"Alzheimer\u2019s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs","volume":"211","author":"Monteiro","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/procel\/pwae026","article-title":"Alzheimer\u2019s disease: Insights into pathology, molecular mechanisms, and therapy","volume":"16","author":"Zheng","year":"2025","journal-title":"Protein Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"Swanson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Aisen","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/S0140-6736(24)01883-X","article-title":"Passive anti-amyloid \u03b2 immunotherapy in Alzheimer\u2019s disease-opportunities and challenges","volume":"404","author":"Heneka","year":"2024","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s13139-024-00848-3","article-title":"Anti-amyloid Antibody Therapies for Alzheimer\u2019s Disease","volume":"58","author":"Park","year":"2024","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","article-title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: Current landscape and future perspectives","volume":"14","author":"Kim","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3233\/ADR-230025","article-title":"Antibody-Mediated Clearance of Brain Amyloid-\u03b2: Mechanisms of Action, Effects of Natural and Monoclonal Anti-A\u03b2 Antibodies, and Downstream Effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3233\/JAD-220262","article-title":"Making the Case for Accelerated Withdrawal of Aducanumab","volume":"87","author":"Whitehouse","year":"2022","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate Use Recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Schreiner, T.G., Croitoru, C.G., Hodorog, D.N., and Cuciureanu, D.I. (2024). Passive Anti-Amyloid Beta Immunotherapies in Alzheimer\u2019s Disease: From Mechanisms to Therapeutic Impact. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051096"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14737175.2025.2546868","article-title":"Donanemab for Alzheimer\u2019s disease: From preclinical research to the clinical application","volume":"25","author":"Dodel","year":"2025","journal-title":"Expert Rev. Neurother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","article-title":"Amyloid-related imaging abnormalities: Manifestations, metrics and mechanisms","volume":"21","author":"Greenberg","year":"2025","journal-title":"Nat. Rev. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ebmental-2018-300014","article-title":"Ten simple rules for conducting umbrella reviews","volume":"21","author":"Radua","year":"2018","journal-title":"Evid.-Based Ment. Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e70017","DOI":"10.1002\/jcv2.70017","article-title":"Guidance for umbrella reviews of observational studies: A scoping review","volume":"6","author":"Zhou","year":"2026","journal-title":"JCPP Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e000071","DOI":"10.1136\/bmjmed-2021-000071","article-title":"Conducting umbrella reviews","volume":"1","author":"Belbasis","year":"2022","journal-title":"BMJ Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/eurjcn\/zvaf012","article-title":"Umbrella reviews: A methodological guide","volume":"24","author":"Fernandez","year":"2025","journal-title":"Eur. J. Cardiovasc. Nurs."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, H., Pan, J., Zhang, M., and Tan, Z. (2025). Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab\/donanemab) in the treatment of early Alzheimer\u2019s disease. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1599048"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3233\/JAD-240161","article-title":"Pharmacologic and Nutritional Interventions for Early Alzheimer\u2019s Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"99","author":"Zeng","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101959","DOI":"10.1016\/j.arr.2023.101959","article-title":"Effects of three kinds of anti-amyloid-\u03b2 drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: A systematic review and meta-analysis of phase II\/III clinical trials in Alzheimer\u2019s disease","volume":"88","author":"Lyu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100473","DOI":"10.1016\/j.tjpad.2025.100473","article-title":"Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence","volume":"13","author":"Qi","year":"2026","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40263-024-01067-2","article-title":"Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer\u2019s Disease: A Systematic Review and Network Meta-Analysis","volume":"38","author":"Qiao","year":"2024","journal-title":"CNS Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Qiao, Y., Chi, Y., Zhang, Q., and Ma, Y. (2023). Safety and efficacy of lecanemab for Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized clinical trials. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1169499"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102981","DOI":"10.1016\/j.arr.2025.102981","article-title":"Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"114","author":"Shim","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.clinme.2025.100336","article-title":"Comparisons of efficacy and safety of immunotherapies for Alzheimer\u2019s disease treatment: A network meta-analysis of randomised controlled trials","volume":"25","author":"Su","year":"2025","journal-title":"Clin. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e70017","DOI":"10.1002\/hup.70017","article-title":"The Efficacy and Safety of Amyloid Beta-Directed Monoclonal Antibodies for Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials","volume":"40","author":"Wei","year":"2025","journal-title":"Hum. Psychopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3233\/JAD-230911","article-title":"Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer\u2019s Disease: A Systematic Review and Network Meta-Analysis","volume":"98","author":"Terao","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s10072-023-07194-w","article-title":"Efficacy of anti-amyloid-\u00df monoclonal antibody therapy in early Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"45","author":"Dantas","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","article-title":"The Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review","volume":"63","author":"Kueper","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer\u2019s research consortium study","volume":"65","author":"Waring","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: A composite clinical outcome for prodromal Alzheimer\u2019s disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Potashman, M., Pang, M., Tahir, M., Shahraz, S., Dichter, S., Perneczky, R., and Nolte, S. (2023). Psychometric properties of the Alzheimer\u2019s Disease Cooperative Study\u2014Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: A post hoc analysis of the ADCS ADC-008 trial. BMC Geriatr., 23.","DOI":"10.1186\/s12877-022-03527-0"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12779\/dnd.2017.16.2.40","article-title":"Subjective Cognitive Decline and Alzheimer\u2019s Disease Spectrum Disorder","volume":"16","author":"Hong","year":"2017","journal-title":"Dement. Neurocognitive Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","article-title":"The characterisation of subjective cognitive decline","volume":"19","author":"Jessen","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13643-022-02029-9","article-title":"AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals","volume":"11","author":"Li","year":"2022","journal-title":"Syst. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) Phase 1b Study in Alzheimer\u2019s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e70293","DOI":"10.1002\/alz.70293","article-title":"TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer\u2019s disease","volume":"21","author":"Salloway","year":"2025","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese Patients with Early Alzheimer\u2019s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of Amyloid Reduction After Donanemab Treatment with Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e237230","DOI":"10.1001\/jamanetworkopen.2023.7230","article-title":"Lecanemab for Patients with Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial","volume":"6","author":"Berry","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100160","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer\u2019s disease","volume":"12","author":"Chen","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer\u2019s Disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_58","first-page":"e12377","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer\u2019s disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401\u2014A clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-Related Imaging Abnormalities with Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13195-022-01129-x","article-title":"Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer\u2019s disease","volume":"14","author":"Dhadda","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e70062","DOI":"10.1002\/alz.70062","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: Real-world outcomes in early Alzheimer\u2019s disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab Treatment in a Specialty Memory Clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00415-025-13142-9","article-title":"Monoclonal antibody administration in an academic institution and private neurological practice: A tale of two clinics","volume":"272","author":"Rosenbloom","year":"2025","journal-title":"J. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center","volume":"11","author":"Shields","year":"2024","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13195-024-01412-z","article-title":"The search for clarity regarding \u201cclinically meaningful outcomes\u201d in Alzheimer disease clinical trials: CLARITY-AD and Beyond","volume":"16","author":"Tarawneh","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1002\/alz.14050","article-title":"Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer\u2019s disease","volume":"20","author":"Lansdall","year":"2024","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/gps.2319","article-title":"The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer\u2019s disease","volume":"25","author":"Rockwood","year":"2010","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40120-022-00352-w","article-title":"Assessing the Clinical Meaningfulness of the Alzheimer\u2019s Disease Composite Score (ADCOMS) Tool","volume":"11","author":"Lenderking","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hu, G., and Zhang, M. (2026). Efficacy and Safety of Donanemab in the Treatment of Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis. Curr. Alzheimer Res., in press.","DOI":"10.2174\/0115672050425914260119063736"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e71361","DOI":"10.1002\/alz.71361","article-title":"Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer\u2019s disease: An update from the Alzheimer\u2019s Association ARIA workgroup","volume":"22","author":"Mahinrad","year":"2026","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMc2215148","article-title":"Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke","volume":"388","author":"Reish","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ajpath.2024.10.014","article-title":"The Amyloid Cascade Hypothesis: A Conclusion in Search of Support","volume":"195","author":"Castellani","year":"2025","journal-title":"Am. J. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","article-title":"Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease","volume":"14","author":"Solopova","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-221305","article-title":"Neuropathology of Anti-Amyloid-\u03b2 Immunotherapy: A Case Report","volume":"93","author":"Castellani","year":"2023","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/17425255.2024.2357637","article-title":"Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer\u2019s","volume":"20","author":"Song","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): Radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain J. Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: A pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/13872877251333084","article-title":"Adverse events associated with lecanemab: A disproportionality analysis of data from the FDA adverse event reporting system","volume":"105","author":"Li","year":"2025","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_84","first-page":"l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"ref_85","first-page":"7","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil. Med. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14283\/jpad.2022.102","article-title":"Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer\u2019s Disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1370\/afm.3050","article-title":"Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis","volume":"22","author":"Ebell","year":"2024","journal-title":"Ann. Fam. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e103048","DOI":"10.1002\/alz70860_103048","article-title":"Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results","volume":"21","author":"Sabbagh","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Feleko\u011flu, E., \u00d6zalevli, S., Yakut, H., Aktan, R., and Yener, G. (2021). Investigation of the Factors Affecting Quality of Life in Patients with Mild to Moderate Alzheimer\u2019s Disease in Terms of Patients and Caregivers. Medicina, 57.","DOI":"10.21203\/rs.3.rs-486899\/v1"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Tonegawa-Kuji, R., Hou, Y., Hu, B., Lorincz-Comi, N., Pieper, A.A., Tousi, B., Leverenz, J.B., and Cheng, F. (2025). Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer\u2019s disease: A systematic review and meta-analysis. PLoS Med., 22.","DOI":"10.1371\/journal.pmed.1004568"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101130","DOI":"10.1016\/j.vhri.2025.101130","article-title":"Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil","volume":"49","author":"Price","year":"2025","journal-title":"Value Health Reg. Issues"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14712598.2026.2631536","article-title":"Efficacy, safety, and ARIA risk of anti-\u03b2-amyloid antibodies in early Alzheimer\u2019s disease: A systematic review, meta-analysis, and meta-regression","volume":"26","author":"Quiroga","year":"2026","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100542","DOI":"10.1016\/j.tjpad.2026.100542","article-title":"Characteristics of infusion-related reactions to lecanemab in early Alzheimer\u2019s disease: A multicenter real-world study in Northwestern China","volume":"13","author":"Liu","year":"2026","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s10072-026-08893-w","article-title":"The evolving landscape of amyloid-targeting therapies in Alzheimer\u2019s disease: Progress and challenges","volume":"47","author":"Zhang","year":"2026","journal-title":"Neurol. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Ono, K., and Tsuji, M. (2020). Protofibrils of Amyloid-\u03b2 are Important Targets of a Disease-Modifying Approach for Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030952"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"103663","DOI":"10.1016\/j.jpet.2025.103663","article-title":"Impacts of anti-drug antibodies on pharmacokinetic and pharmacodynamic actions of cell-permeable middle molecule peptide drug","volume":"392","author":"Gao","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_97","first-page":"e70149","article-title":"Donanemab immunogenicity in participants with early symptomatic Alzheimer\u2019s disease","volume":"11","author":"Mullins","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e066289","DOI":"10.1002\/alz.066289","article-title":"Lecanemab (BAN2401) Infusion Reactions and Immunogenicity: Results from Randomized Phase 2 Study and an Open-Label Extension (OLE)","volume":"18","author":"Landry","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_99","first-page":"030","article-title":"Lecanemab: The advent of biologicals in Alzheimer\u2019s disease, affordability, and clinical relevance","volume":"15","author":"Anil","year":"2025","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/13872877251331243","article-title":"Donanemab eligibility in early Alzheimer\u2019s disease: A real-world study","volume":"105","author":"Urso","year":"2025","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_101","first-page":"e85377","article-title":"A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer\u2019s Disease","volume":"17","author":"Chundu","year":"2025","journal-title":"Cureus"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/13872877251391820","article-title":"Alzheimer\u2019s disease diagnosis and treatment: From pathophysiological insights to therapeutic advances in the era of precision neurology (2025 review)","volume":"109","author":"Kim","year":"2026","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Kurkinen, M., Fu\u0142ek, M., Fu\u0142ek, K., Besz\u0142ej, J.A., Kurpas, D., and Leszek, J. (2023). The Amyloid Cascade Hypothesis in Alzheimer\u2019s Disease: Should We Change Our Thinking?. Biomolecules, 13.","DOI":"10.3390\/biom13030453"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00401-025-02862-x","article-title":"Sequence and trajectory of early Alzheimer\u2019s disease-related tau inclusions in the hippocampal formation of cases without amyloid-\u03b2 deposits","volume":"149","author":"Braak","year":"2025","journal-title":"Acta Neuropathol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Costa, T., and Liloia, D. (2025). Are current etiological theories of Alzheimer\u2019s disease falsifiable? An epistemological assessment. Front. Aging Neurosci., 17.","DOI":"10.3389\/fnagi.2025.1708234"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/JAD-2010-100846","article-title":"Is brain amyloid production a cause or a result of dementia of the Alzheimer\u2019s type?","volume":"22","author":"Struble","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wong-Guerra, M., Calfio, C., Maccioni, R.B., and Rojo, L.E. (2023). Revisiting the neuroinflammation hypothesis in Alzheimer\u2019s disease: A focus on the druggability of current targets. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1161850"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-024-00445-0","article-title":"Neuroinflammation in Alzheimer\u2019s disease: Insights from peripheral immune cells","volume":"21","author":"Zhang","year":"2024","journal-title":"Immun. Ageing"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neuroscience.2026.06.001","article-title":"Cerebral hypoperfusion and the vascular-metabolic-immune-glymphatic network in Alzheimer\u2019s disease: Mechanisms, diagnosis, and therapy","volume":"610","author":"Yao","year":"2026","journal-title":"Neuroscience"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Majdic, G. (2026). The triple-hit hypothesis of Alzheimer\u2019s disease: Blood-brain barrier breakdown, infection, and neuroimmune activation as a unified etiological framework. Front. Neurosci., 20.","DOI":"10.3389\/fnins.2026.1815976"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Lunny, C., Pieper, D., Thabet, P., and Kanji, S. (2021). Managing overlap of primary study results across systematic reviews: Practical considerations for authors of overviews of reviews. BMC Med. Res. Methodol., 21.","DOI":"10.1186\/s12874-021-01269-y"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1002\/alz.13785","article-title":"Generating real-world evidence in Alzheimer\u2019s disease: Considerations for establishing a core dataset","volume":"20","author":"Galvin","year":"2024","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e70662","DOI":"10.1002\/alz.70662","article-title":"Donanemab in preclinical Alzheimer\u2019s disease: Screening and baseline data from TRAILBLAZER-ALZ 3","volume":"21","author":"Yaari","year":"2025","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer\u2019s disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tracli.2024.06.002","article-title":"The Hippocratic principle \u201cto help or at least to do no harm\u201d","volume":"31","author":"Askitopoulou","year":"2024","journal-title":"Transfus. Clin. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"25741","DOI":"10.1038\/s41598-024-75204-8","article-title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer\u2019s disease: A systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","volume":"14","author":"Avgerinos","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/13872877251361044","article-title":"Efficacy and APOE \u03b54-stratified risk of donanemab in Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized clinical trials","volume":"107","author":"Virgilio","year":"2025","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e3592","DOI":"10.1002\/brb3.3592","article-title":"Use of lecanemab for the treatment of Alzheimer\u2019s disease: A systematic review","volume":"14","author":"Hossain","year":"2024","journal-title":"Brain Behav."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JAD-220046","article-title":"Safety and Efficacy of Monoclonal Antibodies for Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials","volume":"87","author":"Lacorte","year":"2022","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Liu, S., Zhao, M., Liu, Y., Yang, X., Yan, H., Xu, H., Wu, Y., and Xu, Y. (2025). Comparative efficacy and safety of symptomatic therapy and disease-modifying therapy for Alzheimer\u2019s disease: A systematic review and network meta-analysis. Front. Neurosci., 19.","DOI":"10.3389\/fnins.2025.1656906"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1007\/s10072-024-07477-w","article-title":"The efficacy and safety of lecanemab 10 mg\/kg biweekly compared to a placebo in patients with Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Abdelazim","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Alkhalifa, A.E., Al Mokhlf, A., Ali, H., Al-Ghraiybah, N.F., and Syropoulou, V. (2025). Anti-Amyloid Monoclonal Antibodies for Alzheimer\u2019s Disease: Evidence, ARIA Risk, and Precision Patient Selection. J. Pers. Med., 15.","DOI":"10.3390\/jpm15090437"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"102620","DOI":"10.1016\/j.arr.2024.102620","article-title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"104","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/13872877251331640","article-title":"Exploring the efficacy and safety of lecanemab in the management of early Alzheimer\u2019s disease: A systematic review of clinical evidence","volume":"105","author":"Ashmawy","year":"2025","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuroscience.2024.11.029","article-title":"Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer\u2019s disease: A systematic review and network meta- analysis","volume":"565","author":"Cao","year":"2025","journal-title":"Neuroscience"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14712598.2024.2416947","article-title":"A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer\u2019s disease","volume":"24","author":"Chhabra","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuroscience.2025.10.011","article-title":"Anti-amyloid monoclonal antibody therapies in Alzheimer\u2019s disease\u2014A scoping review","volume":"589","author":"Elamin","year":"2025","journal-title":"Neuroscience"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s40120-023-00541-1","article-title":"Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer\u2019s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion","volume":"12","author":"Esquer","year":"2023","journal-title":"Neurol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1177\/13872877251404505","article-title":"Severe symptomatic amyloid-related imaging abnormalities in Alzheimer\u2019s disease: Two case reports and systematic review of reported cases","volume":"109","author":"Hilario","year":"2026","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"25424823261422205","DOI":"10.1177\/25424823261422205","article-title":"Network meta-analysis of the efficacy of nine drugs for cognitive function in patients with Alzheimer\u2019s disease","volume":"10","author":"Huang","year":"2026","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e68454","DOI":"10.2196\/68454","article-title":"Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis with a Web Application","volume":"27","author":"Jeremic","year":"2025","journal-title":"J. Med. Internet Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4103\/aian.aian_547_24","article-title":"The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer\u2019s Dementia: A Systematic Review","volume":"28","author":"Mostafa","year":"2025","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Rashad, A., Rasool, A., Shaheryar, M., Sarfraz, A., Sarfraz, Z., Robles-Velasco, K., and Cherrez-Ojeda, I. (2022). Donanemab for Alzheimer\u2019s Disease: A Systematic Review of Clinical Trials. Healthcare, 11.","DOI":"10.3390\/healthcare11010032"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.neurol.2022.06.012","article-title":"High-clearance anti-amyloid immunotherapies in Alzheimer\u2019s disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects","volume":"178","author":"Villain","year":"2022","journal-title":"Rev. Neurol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s43441-022-00390-4","article-title":"Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer\u2019s Disease","volume":"56","author":"Wang","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: A systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6782\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:47:34Z","timestamp":1788252454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":138,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176782"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176782","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}